Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.

In the latest trading session, Eli Lilly (LLY) closed at $773.29, marking a +1.07% move from the previous day.

It hasn't been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.

If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors.

If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's imp...

It seems like just yesterday that vaccines used to combat the COVID-19 pandemic were all anyone in the medical world could talk about. Companies such as Pfizer, Moderna, and Johnson & Johnson captu...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Eli Lilly (LLY -0.08%) is generating billions in cash flow growth due to product innovation.

Eli Lilly and Co (NYSE:LLY) is in focus today, after the U.S. Food & Drug Administration (FDA) approved its weight-loss drug, Zepbound, to treat obstructive sleep apnea in adults with obesity -- th...

These three stocks, which are at or near the top of their respective industries, just increased dividends by double-digit percentages. Below, I'll reveal how much these companies are paying out to ...

FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.

Eli Lilly (LLY 1.35%) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market...

Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly boost your long-term returns by automatically reinvesting their payouts. F...

Since pharmaceutical giant Eli Lilly (LLY 1.35%) reported earnings for the third quarter on Oct. 30, shares have been punished by investors. As of this writing, Lilly's stock price has plunged as m...